Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01083758 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01083758 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 31 participants.
The verdict
NCT01083758, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of once daily use of LEO 80185 topical suspension in adolescent subjects (aged 12 to 17 years) with scalp psoriasis. LEO 80185 topical suspension has marketing approval in many countries under the brand names Taclonex Scalp® Topical Suspension and Xamiol® gel for the treatment of scalp psoriasis in adults. No studies have been performed in subjects younger than 18 years.
Interventions
- DRUG LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01083758
The ClinicalTrials.gov registry entry for NCT01083758 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) is the first listed.
NCT01083758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01083758 about?
NCT01083758 is a clinical study titled "Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis". The purpose of the study is to evaluate the safety and efficacy of once daily use of LEO 80185 topical suspension in adolescent subjects (aged 12 to 17 years) with scalp psoriasis. LEO 80185 topical suspension has marketing approval in many countries under the brand names Taclonex Scalp® Topical Sus...
What is the current status of trial NCT01083758?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2010-04. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01083758?
The interventions under investigation include: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) (DRUG).
Who is sponsoring clinical trial NCT01083758?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.